Central sleep apnoea due to a medication or substance (Q41280): Difference between revisions
From determinar.ia.br - Determine suas informações
Created a new Item |
Changed an Item |
||||||||||||||
| (7 intermediate revisions by the same user not shown) | |||||||||||||||
| description / pt-br | description / pt-br | ||||||||||||||
A apneia do sono central devida a medicação é caracterizada por um padrão de apneia ou hipopneia central recorrente (mais de cinco por hora) atribuível ao uso de medicação ou substância química, mais comumente opioides de longa duração (p. ex. metadona, morfina ou oxicodona de longa ação, adesivos de fentanil). O distúrbio é suficientemente grave para causar sintomas como sonolência diurna, sono agitado, despertar por dispneia ou roncos. Apneias obstrutivas e hipoventilação podem estar presentes, mas a apneia do sono central é o achado predominante._x000D_ _x000D_ NOTA: o diagnóstico definitivo requer evidência objetiva baseada em polissonografia, no contexto de uso de medicação ou substância considerada causadora dos sintomas. | |||||||||||||||
| description / en | description / en | ||||||||||||||
Central sleep apnoea due to a medication is characterised by a pattern of recurring, predominantly central sleep apnoea or hypopnoea (more than five per hour) that is attributable to a medication or substance, most commonly long-acting opioids (e.g. methadone, long-acting morphine or oxycodone, fentanyl patches). The disturbance is sufficiently severe to cause symptoms such as daytime sleepiness, disturbed sleep, awakening with dyspnoea, or snoring. Obstructive apnoeas and hypoventilation may be present, but central sleep apnoea is the predominant finding. Note: A definitive diagnosis requires objective evidence based on polysomnography in the context of medication or substance use that is judged to be causing the symptoms. | |||||||||||||||
| Property / Canonical URI | |||||||||||||||
| Property / Canonical URI: https://id.who.int/icd/entity/2012656262 / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / CURIE | |||||||||||||||
CID11:7A40.6 | |||||||||||||||
| Property / CURIE: CID11:7A40.6 / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / Canary Token | |||||||||||||||
dki-india-7A40.6 | |||||||||||||||
| Property / Canary Token: dki-india-7A40.6 / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / Verification Status | |||||||||||||||
Concluído | |||||||||||||||
| Property / Verification Status: Concluído / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / Knowledge Architect | |||||||||||||||
| Property / Knowledge Architect: https://pauloleads.com.br/cases-publicos/ / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / Collection date | |||||||||||||||
13 August 2026
| |||||||||||||||
| Property / Collection date: 13 August 2026 / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / Linked ICD 10 | |||||||||||||||
| Property / Linked ICD 10: G47.3 / rank | |||||||||||||||
Normal rank | |||||||||||||||
Latest revision as of 07:23, 13 August 2026
Central sleep apnoea due to a medication is characterised by a pattern of recurring, predominantly central sleep apnoea or hypopnoea (more than five per hour) that is attributable to a medication or substance, most commonly long-acting opioids (e.g. methadone, long-acting morphine or oxycodone, fentanyl patches). The disturbance is sufficiently severe to cause symptoms such as daytime sleepiness, disturbed sleep, awakening with dyspnoea, or snoring. Obstructive apnoeas and hypoventilation may be present, but central sleep apnoea is the predominant finding. Note: A definitive diagnosis requires objective evidence based on polysomnography in the context of medication or substance use that is judged to be causing the symptoms.
| Language | Label | Description | Also known as |
|---|---|---|---|
| default for all languages | 7A40.6 |
||
| English | Central sleep apnoea due to a medication or substance |
Central sleep apnoea due to a medication is characterised by a pattern of recurring, predominantly central sleep apnoea or hypopnoea (more than five per hour) that is attributable to a medication or substance, most commonly long-acting opioids (e.g. methadone, long-acting morphine or oxycodone, fentanyl patches). The disturbance is sufficiently severe to cause symptoms such as daytime sleepiness, disturbed sleep, awakening with dyspnoea, or snoring. Obstructive apnoeas and hypoventilation may be present, but central sleep apnoea is the predominant finding. Note: A definitive diagnosis requires objective evidence based on polysomnography in the context of medication or substance use that is judged to be causing the symptoms. |
Statements
CID11:7A40.6
0 references
dki-india-7A40.6
0 references
Concluído
0 references
13 August 2026
0 references
